Leukaemias in Zambia

TO THE EDITOR
There are distinct differences between subSaharan Africa and the industrialized countries as to the age and gender distributions of the leukaemias. 1 In subSaharan Africa, incidence of acute lymphoblastic leukaemia (ALL) is low (Ͻ1/100 000/year); the deficit is specifically of common ALL (c-ALL) in children under 5 years of age. 2 T-ALL is the more common form with a peak frequency at 5 to 14 years of age. 1 In the past 12 years, however, c-ALL has been observed with increasing frequency in Black children in South Africa and Zimbabwe. 3, 4 Acute myeloid leukaemia (AML) is diagnosed with equal frequency as ALL in children in tropical Africa, and is especially common in boys aged 5 to 14 years, who present often with chloromas, usually arising in the orbit. 1 Chronic granulocytic leukaemia (CGL) is seen generally at younger ages and up to 20% of CGL in some series occurred in children. 1 In tropical Africa, chronic lymphocytic leukaemia (CLL) shows a male to female (M:F) ratio of 1:1 overall, but below the age of 45 years the M:F is 1:2, while above that age it is 2:1 as in the western world. The 'African' CLL in younger mostly female adults is associated with multiparity, poverty and rural habitation. Patients present typically with gross splenomegaly and only moderate lymphadenopathy. 5 From the few reports of leukaemias in Zambians it may be concluded that age and gender distributions of leukaemias in Zambia resemble those of other subSaharan tropical African countries. 6 The present communication describes the age-specific frequencies and gender distributions of the leukaemias diagnosed over a 3-year period (1995) (1996) (1997) in the capital city, Lusaka. Attention was focused on whether there was an increase in the frequency of cALL in childhood, and on the immunophenotypic classification of the chronic lymphoproliferative disorders presenting as CLL. Cells from patients presenting from May 1996 onwards with acute leukaemias and chronic lymphoproliferative disorders were subjected to immunophenotyping utilizing the FACScan. The research protocol was approved by the Research Ethics Committee of the University of Zambia.
ALL was seen in 11 children (eight males, three females) aged less than 15 years, and 16 adults (nine males, seven females): only four were aged less than 5 years. Overall the M:F ratio was 1:0.59 ( Figure  1 ). FAB classification was L1 in four, L2 in 21 and L3 in two.
Immunophenotyping was performed on nine ALL. Seven carried T cell markers. Three were pre T-ALL (CD7+ve, CD3+ve, CD2−ve, CD5−ve, CD4−ve, CD8−ve). One was early T-ALL (CD7+ve, CD3+ve, CD2+ve, CD5+ve, CD4−ve CD8−ve). Three were cortical T-ALL (CD7+ve, CD3+ve, CD2+ve, CD5+ve, CD4+ve CD8± in two, and CD4+ve CD8+ve in one). The patients with T-ALL were five males (aged 4 to 20 years) and two females (aged 32 and 37 years): two of the seven were children. Two ALL were classified as c-ALL (CD19+ve, CD22+ve, CD10+ve): the patients were a male aged 10 and a female aged 20 years. The distribution of ALL by age, gender and FAB classification was typical for tropical Africa.
1,2 T-ALL was the commonest phenotype (seven out of nine tested), and arose from cells of varying degrees of differentiation from pre-T to cortical T cells. Neither of the two patients with cALL was aged below 5 years. There is not yet in Zambia any apparent increase in the frequency of c-ALL in childhood, as has been described in the Black populations of South Africa and Zimbabwe. 3, 4 Whatever are the changes in the environment which have increased the risk of developing cALL in childhood in southern Africa, such as improved hygiene delaying exposure to certain infections, population mixing resulting from urbanization and no prolonged breastfeeding, these have not yet had any impact on the frequency of the disease in Zambia. c-ALL remains a rarity in Zambian adults also, as it does in South Africa. 3 AML was diagnosed in eight children (four males, four females), and nine adults (four males, five females). The overall M:F was 1:1.13 ( Figure 1 ). None had chloroma at the time of presentation, but this has been described in a previous Zambian study. 6 The most common FAB classification was M1 (five), followed by M2 (four) and M3 (four, of which three were hypogranular variants): other types seen were M4, M5 (one each) and M6 (two). AML was confirmed immunophenotypically in all five tested (CD13+ve, CD33+ve).
Of the 19 patients with CGL, five (21%) were children, the youngest patient being a girl aged 6 years. The overall M:F was 1:0.91 ( Figure  1 ). One leukaemia was in the accelerated phase and three were in blastic crisis when first diagnosed. Immunophenotypic markers demonstrated that one blastic transformation was myeloid.
It is probable that the high relative frequency in childhood and young adults reflects not a high age specific incidence, but only the distribution by age of the population. 1 The high relative frequency of CGL in childhood (5/24 leukaemias) could also be a result of its more indolent course compared to acute leukaemias, and hence a greater chance of presentation at hospital.
Three men and nine women had CLL (M:F = 1:3). Three women were aged less than 45 years, of whom two were diagnosed on light microscopy as having prolymphocytic leukaemia (PLL) (Figure 1) . None had cells suggestive of hairy cell leukaemia (HCL) or splenic lymphoma with villous lymphocytes (SLVL). Typical B-CLL was con-
Figure 1
Age and gender distribution of 27 Zambians with acute lymphoblastic leukaemia (ALL), 17 with acute myeloid leukaemia (AML), 19 with chronic granulocytic leukaemia (CGL), and 12 with chronic lymphocytic laukaemia (CLL).`, Male; Ǣ, Female. * Prolymphocytic leukaemia.
firmed immunophenotypically in two women aged 82 and 57 years (CD5+ve, CD19+ve, CD20+ve, CD23+ve). One morphological PLL in a woman aged 38 showed pan B-cell markers (CD19+ve, CD20+ve), but was atypical for B-CLL (CD5−ve, CD22+ve, CD23 weak positive). Other markers were CD11c+ve, CD25+ve, and and positive. One woman aged 62 years with CLL diagnosed on light microscopy had a similar pattern of pan B-cell markers (CD19+ve, CD20+ve) and atypical B-CLL markers (CD5−ve, CD22+ve, CD23−ve, and and indeterminate), but was not tested for CD11c and CD25.
We confirmed that CLL occurs predominantly in women and at a relatively younger age in Zambia, as in other subSaharan countries. 1, 5, 6 It is postulated that recurrent malaria and other infections result in a polyclonal B cell proliferation, which in an extreme form is hyperreactive malarial splenomegaly (HMS). Proliferation is greatest with more frequent exposure to infection associated with rural poverty, and with the recurrent depression of cell mediated immunity during pregnancy of grandemultiparae. A second event leading to transformation to a monoclonal proliferation could be an infection by an unidentified virus, whose transmission is more frequent in impoverished rural communities, and whose impact is enhanced by the depression of immunity by malaria and pregnancy. 5 The two youngest women had PLL on cytology. One immunophenotyping confirmed a B cell origin and the atypicality of CLL: the cells were CD11c positive, and the leukaemia was classified as B-PLL, with CD11c positivity. The leukaemic cells from another woman with CLL also had immunophenotypic markers compatible with B-PLL. These findings differed from those of Bates and colleagues 7 in Ghana, where similar patients are described but with villous lymphocytes which were CD11c negative. We postulate that throughout tropical Africa there prevail conditions causing a large polyclonal expansion of Blymphocytes. In west Africa a second factor leads to the emergence of SLVL. In central Africa a different second factor causes a condition more closely resembling B-PLL. A multicentre study is required with the objective of identifying risk factors and characterizing the chronic lymphoproliferative disorders resembling CLL in Africa. With a clearer understanding of these disorders, therapy could be better directed, and possibly steps taken towards prevention.
The Zambian patients included in this study were treated following standard protocols as far as was possible despite shortages of cytotoxic drugs and the difficulties for patients to attend when living long distances from the hospital. Any discussion of outcome of treatment was rendered meaningless because of the frequency with which regimens were interrupted. Patients with leukaemia in tropical Africa have benefited little or not at all from the advances in therapy of the past decades, but a major investment into haemato-oncology in tropical Africa should be followed by commensurate humanitarian benefit. One possible way towards sustainable haemato-oncology services in selected centres in subSaharan Africa is twinning with centres in industrialized countries. An example of a successful paediatric haematooncology twinning is the Italian-Swiss cooperation with Nicaragua in the La Mascota Programme. 8 The advantages for the centre in the developing country are (1) rational and sustained treatment for patients; (2) education of laboratory, nursing and medical staff in a modern oncology service; and (3) training in research methods. The advantages for personnel from the centre in the developed country are (1) experience gained from exposure to a whole range of malignant diseases; (2) opportunities for both fundamental and clinical research; (3) the stimuli from living in an unfamiliar community and environment; and (4) a sense of fulfilment.
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